PALO ALTO, Calif., May 30, 2019 /PRNewswire/ -- Kodiak Sciences
Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, today announced that management
will present at the Jefferies 2019 Healthcare Conference in
New York, NY on Thursday, June 6 at 2:00
p.m. Eastern Time.
A live webcast of the presentation will be available on the
"Investors & Media" section of Kodiak's website at
http://ir.kodiak.com/ and will remain available for replay for
a limited time following the event.
About Kodiak Sciences Inc.
Kodiak™ is a clinical-stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases. We are focused on bringing new
science to the design and manufacture of next generation retinal
medicines to prevent and treat the leading causes of blindness
globally. Our ABC Platform™ merges the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed as a
potential first-line agent for retinal vascular diseases including
age-related macular degeneration and diabetic eye diseases. Kodiak
has leveraged its ABC Platform to build a pipeline of product
candidates in various stages of development including KSI-501, our
bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of
neovascular retinal diseases such as wet AMD and diabetic
retinopathy. Kodiak is based in Palo
Alto, CA. For more information, visit www.kodiak.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-the-jefferies-2019-healthcare-conference-300859591.html
SOURCE Kodiak Sciences Inc.